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PERSPECTIVE
Neurofibrillary tangles in Alzheimer’s 
disease: elucidation of the molecular 
mechanism by immunohistochemistry 
and tau protein phospho-proteomics
As a key contributor to memory storage, the synapse is one 
of the earliest affected neuronal components in Alzheimer´s 
disease (AD). Under physiological conditions, the synaptic con-
nections between neurons undergo activity-dependent func-
tional and morphological re-organisation. This dynamic, ‘plastic’ 
neural ability critically depends on the structural integrity of 
the synapse. Thus, proteins that are implicated in preserving the 
organisation and dynamics of synaptic connections, including 
microtubules of the cytoskeleton and associated proteins, have 
attracted much focus for their involvement in the malfunction-
ing AD synapse.
Neurofibrillary tangles (NFTs) are a fundamental neuro-
pathological hallmark of AD. NFT-bearing neurons have been 
characterised by loss of cytoskeletal microtubules and tubu-
lin-associated proteins. Although the exact molecular mecha-
nisms linking the loss of cytoskeletal elements to NFT develop-
ment remain unclear, signal transduction pathways involving 
protein phosphorylation and de-phosphorylation are likely to 
play a central role in the formation of neurofibrillary lesions 
(Figure 1). For instance, the major constituent of NFTs, the 
microtubule-associated protein tau (Mapt), is abnormally phos-
phorylated (hyperphosphorylated) in the brains of AD patients 
compared to non-demented individuals (Zempel and Mandel-
kow, 2014). Hyperphosphorylation occurs in an epitope-specific 
manner during the course of AD, and is known to underlie the 
missorting of tau from a primarily axonal to a somatodendritic 
location in neurons. This alteration is thought to contribute not 
only to the deregulation of microtubule dynamics, but also to 
tau polymerisation and aggregation (Alonso et al., 2008).
Conceivably, investigating the molecular mechanisms behind 
the causes and consequences of Mapt hyperphosphorylation 
may lead to an improved understanding of the protein’s role in 
NFT formation, and further elucidate the connection between 
NFT deposition, synaptic loss and memory impairment in AD. 
Interestingly, formation of NFTs and synapse loss are correlated 
during the course of AD (Gomez-Isla et al., 1997) and each of 
these processes further correlates with cognitive decline, argu-
ing that these AD lesions occur in a related, rather than inde-
pendent manner.
Immunohistochemistry of phospho-sites related to Mapt in 
human post-mortem brain and in mice with amyloid patholo-
gy: The regional progression of neurofibrillary lesions is highly 
stereotyped in the AD brain. In their landmark study of 1991, 
Braak and Braak used post-mortem tissue from demented and 
non-demented individuals to summarise three stages of prop-
agation of tau-related pathology (Braak and Braak, 1991). In 
the Braak staging system, NFTs appear initially in the trans-en-
torhinal region of the temporal lobe, spreading to limbic areas 
such as the hippocampus, and finally affecting large areas of the 
neocortex.
In addition to the region-specific spread of NFTs, distinct 
morphological stages of NFT formation have been also dis-
cerned in the AD brain. Each individual stage has been asso-
ciated with characteristic patterns of Mapt hyperphosphor-
ylation, suggesting that specific phosphorylation events may 
contribute to the evolution of tau pathology (Augustinack et 
al., 2002). Thus, pre-NFTs are typically observed as punctuate 
or diffuse tau inclusions within the cytoplasm of an otherwise 
normal-looking neuron, and are preferentially labelled by anti-
bodies to tau phospho-epitopes pSer262, pThr153 and pThr231. 
Mature NFTs, most intensely stained with antibodies to tau 
epitopes of pThr175/181, pSer46, pSer214, pSer262/pSer356 
and pSer422 are compact filamentous aggregates of cytoplas-
mic tau that invariably displace the cell nucleus towards the 
periphery of the soma. Extracellular, ‘ghost’ NFTs result from 
the death of the host neuron, comprising substantial amounts 
of filamentous tau protein, and are recognized by the absence 
of a stainable nucleus. Extracellular tangles are preferentially 
stained with antibodies AT8 and PHF1 recognizing pSer202/
pThr205 and pSer396/pSer404, respectively. The fact that the 
phosphorylation of specific tau epitopes corresponds to distinct 
stages of NFT formation clearly points towards a sequence of 
early vs. late phosphorylation events, underlying the initiation 
and progression of tau lesions in AD. Indeed, it has been pro-
posed that phosphorylation at Thr231 is an initiating event for 
the formation of NFTs, followed by oligomeric tau aggregation, 
filament formation, and neuronal cell death (Lasagna-Reeves et 
al., 2012). 
The characterisation of tau pathology has been performed in 
several mouse models of amyloidosis, albeit not in an exhaus-
tive manner. Although the general consensus is that amyloidosis 
models do not recapitulate AD tau lesions in terms of NFT for-
mation, amount and propagation, a growing body of preclinical 
studies has shown amyloid beta-induced phosphorylation of 
endogenous mouse tau in vivo, using antibodies to the afore-
mentioned tau epitopes and techniques such as immunohisto-
chemistry and western blotting (Stancu et al., 2014). 
Several reasons might explain why the site-specific phosphor-
ylation of tau in amyloidosis models does not translate to robust 
neurofibrillary pathology, as in AD patients. First, adult mice 
are known to express fewer tau isoforms than humans (three vs. 
six), and are perhaps less liable to increases in endogenous tau 
phosphorylation. Second, the mouse lifespan might be too short 
for the complete sequence of neurofibrillary pathology to unfold 
in models of amyloidosis. Third, unidentified phosphorylation 
sites and/or additional post-translational modifications (PTMs) 
of endogenous mouse tau may render this species resistant to 
the development of NFTs. 
Phospho-proteomics to characterise tau-related lesions in 
amyloidosis models: Only a handful of studies have assessed 
tau PTMs in mouse models of amyloidosis using mass spec-
trometry. In a comprehensive study of amyloid precursor pro-
tein (APP) transgenic mice harboring the human Swedish and 
Indiana mutations (J20 line), Morris et al. confirmed 41 and 
identified 22 novel tau modifications, including phosphoryla-
tions, methylations, acetylations and ubiquitinations (Morris et 
al., 2015). The majority of altered phosphorylation sites of Mapt 
were adjacent to the microtubule-binding repeat domain, and 
were comparable in number with phosphosites identified from 
wild-type mice or post-mortem brain tissue from non-demented 
humans (Funk et al., 2014). These results indicate that the num-
ber of phosphosites of endogenous tau is similar in wild-type 
mice, J20 transgenic animals and cognitively healthy individuals. 
Interestingly, AD ‘diagnostic’ tau epitopes, including pThr181, 
pThr231, pSer202 and pSer404 were commonly detected in both 
control mice and non-AD humans, suggesting either that addi-
tional tau modifications are involved in the formation of NFTs 
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or/and that the excess phosphorylation of the aforementioned 
epitopes, rather than phosphorylation per se, underlies the de-
velopment of NFTs. 
Unlike J20 mice, our integrated quantitative phospho-pro-
teomics study in 12 months old APPswe/Presenilin 1 (PS1)ΔE9 
male transgenic mice demonstrated differences in tau phos-
phorylation compared to age-matched controls within four 
selected brain regions (Kempf et al., 2016). The levels of mul-
tiple phosphopeptides, corresponding to sites Thr58, Ser688/
Thr695, Ser506, Ser494, Ser696, Thr473 and Thr523 of the 
canonical tau sequence in the olfactory bulb, Ser688/Thr695 in 
the neocortex, Ser494 and Thr58 in the brainstem, and Ser688/
Ser696, Ser490/Ser491 as well as Ser688/Ser692/Ser696 in the 
hippocampus, were altered in APPswe/PS1ΔE9 mice compared 
to wild-type littermates. Of the aforementioned peptides, only 
Ser506 is a known phosphosite of Mapt reported by the Phos-
phoSitePlus database. While increased levels of phosphory-
lation were observed for Ser688/Thr695 in the APPswe/PS1ΔE9 
cortex, hippocampal phosphopeptides were decreased com-
pared to control, and a mixed picture of both increases and 
decreases in peptide phosphorylation were observed in the 
transgenic mouse olfactory bulb and the brainstem. For exam-
ple, levels of Mapt-Thr58 were higher in the olfactory bulb, but 
lower in the brainstem of APPswe/PS1ΔE9 mice compared with 
wild-type animals. In contrast, levels of Mapt-Ser494 were 
increased in the brainstem, but reduced in the olfactory bulb 
of transgenic vs. wild-type mice. It is intriguing to speculate 
that the phosphorylation changes on MaptThr58 and Ser494, 
which occurred in opposite directions in the olfactory bulb 
and brainstem of APPswe/PS1ΔE9 mice, may be associated with 
the presence and absence of Gallyas-positive lesions in these 
brain areas, respectively (Kempf et al., 2016).
Our phosphoproteomics approach further revealed that Ser16 
phosphorylation of the microtubule-binding protein stathmin1 
was decreased in the cortex, but increased in the olfactory bulb 
of APPswe/PS1ΔE9 compared to wild-type mice (Kempf et al., 
2016). Because stathmin1 phosphorylation has been shown to 
induce microtubule destruction and subsequent hyperphos-
phorylation of tau (Figure 1), it seems reasonable to suggest 
that stathmin1-mediated mechanisms may be associated with 
neurofibrillary lesions in the cortex, but not in the olfactory 
bulb. Moreover, phospho-14-3-3 proteins, which are directly 
involved in the phosphorylation of tau (Figure 1) via GSK3β, 
were markedly increased in the olfactory bulb over control lev-
els, but remained unaltered in the cortex.
These data suggest that mechanisms and signalling path-
ways known to mediate the phosphorylation of tau in vivo are 
likely to induce neurofibrillary lesions in APPswe/PS1ΔE9 mice 
in a brain region specific manner. To further illustrate the 
complexity of Mapt modulation, endogenous mouse tau has 
been previously shown to be differentially phosphorylated in 
post-synaptic density fractions vs. whole brain lysates of wild-
Figure1 Neuronal phospho-signallingand tangle formation.
The figure shows a post-synaptic neuron with its nucleus. After stimulation of ion-channels and/or G protein-coupled receptors via neurotransmitters origi-
nating from the presynapse, phospho-signalling associated with long-term potentiation (activation of phosphorylation) or long-term depression (suppression 
of phosphorylation), including Ca2+-, MAPK, PI3K or cAMP-mediated signalling is activated/inhibited. This can lead to changes in the phosphorylation 
status of down-stream targets such as stathmin1 or 14-3-3 proteins, which may in turn induce an altered phosphorylation profile of tau protein that can 
eventually culminate in NFT formation. Neuronal cellular metabolism is also important in this process, where cell cycle signalling may lead to an increased 
phosphorylation of Cdk proteins affecting NFT formation. Phosphorylation defects in stathmin1, 14-3-3 and Cdk (such as Cdk5) proteins have been shown 
to be involved in Alzheimer´s neuropathology. cAMP: Cyclic adenosine monophosphate; Cdk: cyclin-dependent kinase; MAPK: mitogen-activated protein 
kinases; NFT: neurofibrillary tangles; PI3K: phosphoinositide 3-kinase. The figure was generated by images from commercial software (http://www.visi-
science.com).
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type animals, demonstrating a cellular compartment specific 
aspect of tau regulation in the brain (synapse vs. soma; Morris 
et al., 2015).
Conclusion and future perspective/application: Using mass 
spectrometry, bioinformatics and a double transgenic model 
of AD, we previously identified novel phosphosites on en-
dogenous ‘wild-type’ mouse tau and other microtubule-regu-
lating proteins. The observed phospho-proteome alterations 
were characterised by a brain area-specific signature and were 
associated with the presence of argyrophilic lesions in the 
olfactory bulb, cortex, hippocampus, but not the brainstem 
of APPswe/PS1ΔE9 mice. These data demonstrate the utility of 
combining phospho-proteomics with in situ labelling tech-
niques to link novel tau modifications to the development of 
NFTs in AD research. 
Several important points can be made from the very lim-
ited number of studies that have assessed PTMs at physio-
logical levels of mouse tau by using mass-spectrometry. No-
tably, studies of Kempf et al. (2016) and Morris et al. (2015) 
indicate differences in tau modification that are amyloidosis 
model-specific. Despite methodological differences in the 
workflow between the two studies, the fact that endogenous 
tau was modified in APPswe/PS1ΔE9, but not J20 transgenic 
mice, invites further consideration of PS1´s role in tau regula-
tion. From a technical point of view, it is clear to us that mass 
spectrometry should be run on both tau insoluble and soluble 
fractions, to enable a complete picture of the phospho-pro-
teome contributing to the development of NFTs in the cell/
brain tissue. Moreover, our efforts to characterise phospho-
sites on Mapt and other proteins should be quantitative rather 
than limited to basic event identification, as shown by Di Do-
menico et al. (2011) in the hippocampus of AD patients using 
2D gels. Thus, it is necessary to normalise the quantitative 
data of the phospho-proteome against the proteome to ensure 
that the noted changes on phosphorylation levels are due to 
phosphorylation itself and not due to expression changes 
in the proteome, as originally proposed by the lab of Steven 
Gygi (Harvard Medical School, Boston, USA). This quantita-
tive approach would be also advantageous in relation to the 
bioinformatics analysis of signalling pathways and pathway 
networks, which would be rendered more accurate/physio-
logically relevant.
Translating phospho-proteomics observations from murine 
models of familial AD to AD patient brains is warranted, al-
beit not without caveats. A key challenge relates to the long 
post-mortem interval times for obtaining human tissue, a delay 
which may itself induce secondary and tertiary processes in the 
(phospho-)proteomic profiles, obscuring changes due to the 
primary causes of AD (Brinkmalm et al., 2015). Furthermore, it 
is rather difficult to obtain brain biopsy samples from patients 
at the early stages of AD, and thus surrogate markers, such as 
those in the cerebrospinal fluid may need to be collected and 
studied. Another point to be addressed is the assessment of 
adequate sample size in order to reach meaningful statistical 
conclusions from experiments involving human material. Last 
but not least, there is a clear need to harmonise experimental 
protocols on an international level, particularly in the neuro-
proteomics community, so as to enable result comparisons and 
minimize technical variation. We believe that quantitative pep-
tide labelling approaches such as TMT or iTRAQ together with 
an internal standard spiked in before processing the samples 
would improve comparison of performance between different 
laboratories.
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